Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,299,977
  • Shares Outstanding, K 67,448
  • Annual Sales, $ 250,730 K
  • Annual Income, $ -618,700 K
  • 60-Month Beta 1.75
  • Price/Sales 9.12
  • Price/Cash Flow N/A
  • Price/Book 1.90
Trade BLUE with:

Options Overview

Details
  • Implied Volatility 74.16%
  • Historical Volatility 34.98%
  • IV Percentile 76%
  • IV Rank 29.93%
  • IV High 124.24% on 03/26/21
  • IV Low 52.77% on 01/21/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 13,412
  • Volume Avg (30-Day) 2,705
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 33,039
  • Open Int (30-Day) 33,791

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -3.15
  • Number of Estimates 12
  • High Estimate -2.91
  • Low Estimate -3.44
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -775.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.35 +14.28%
on 05/19/21
35.59 -5.76%
on 06/14/21
+3.22 (+10.62%)
since 05/14/21
3-Month
26.74 +25.43%
on 04/21/21
35.59 -5.76%
on 06/14/21
+1.11 (+3.42%)
since 03/12/21
52-Week
24.24 +38.37%
on 02/23/21
68.39 -50.96%
on 08/06/20
-30.39 (-47.54%)
since 06/12/20

Most Recent Stories

More News
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc....

BLUE : 33.32 (-2.29%)
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.

BMY : 67.01 (-0.49%)
MRK : 75.32 (-1.25%)
RGEN : 195.42 (+2.04%)
BLUE : 33.32 (-2.29%)
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for B-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual

--Across Phase 3 studies, 89% (32/36) of evaluable patients across ages and genotypes achieved TI and remain transfusion free, including 91% (20/22) of evaluable pediatric patients under the age of 18

BLUE : 33.32 (-2.29%)
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

BIIB : 404.83 (+2.06%)
JNJ : 164.85 (-0.07%)
ALXN : 181.34 (-0.17%)
INCY : 82.28 (-0.36%)
BLUE : 33.32 (-2.29%)
ARGX : 318.83 (+1.32%)
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

RGEN : 195.42 (+2.04%)
TECH : 449.26 (+1.20%)
BLUE : 33.32 (-2.29%)
KMDA : 5.90 (-0.68%)
bluebird bio to Present at Goldman Sachs Global Healthcare Conference

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET.

BLUE : 33.32 (-2.29%)
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and B-Thalassemia Studies

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for...

BLUE : 33.32 (-2.29%)
Why Is Bluebird (BLUE) Up 3.5% Since Last Earnings Report?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BLUE : 33.32 (-2.29%)
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of...

BLUE : 33.32 (-2.29%)
bluebird bio Receives Positive CHMP Opinion for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

--As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability (MFD)-free survival at two years...

BLUE : 33.32 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

3rd Resistance Point 35.62
2nd Resistance Point 34.99
1st Resistance Point 34.55
Last Price 33.32
1st Support Level 33.48
2nd Support Level 32.85
3rd Support Level 32.41

See More

52-Week High 68.39
Fibonacci 61.8% 51.52
Fibonacci 50% 46.31
Fibonacci 38.2% 41.11
Last Price 33.32
52-Week Low 24.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar